Companies
BioMarin
Delivery platforms — Vector engineering.
- Country
- United States
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $3.7 billion in debt financing for the Amicus Therapeutics acquisition, with $850 million in senior unsecured notes issued in Feb 2026 (2025-12-31) | sec.gov |
| Capacity | 10,000 doses per year combined for valoctocogene roxaparvovec and BMN 307 (2020-09-24) | biomarin.com · prnewswire.com |
| Certification | ISO 14001 and ISO 45001 at both manufacturing sites (2024-01-19) | biomarin.com |
| Certification | cGMP certified by the EMA for the Novato, California vector production facility (2020-06-30) | prnewswire.com |
| Revenue | $3.221 billion for the full year 2025 (2025-12-31) | investors.biomarin.com · sec.gov |
| Production site | Novato, California, USA | biomarin.com |
| Production site | Shanbally, County Cork, Ireland | biomarin.com |
Independent sources: prnewswire.com · sec.gov
Technologies
No articles yet.
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.